Out-licensing
- Out-licensing
- View
Immunohistochemistry-based prognostic test for colon cancer
Full description
The product is an immunohistochemistry (IHC)-based prognostic test, to be performed on clinical samples obtained from curatively intended surgery of colon cancer patients. IHC-based tests are quite simple to perform and well established among relevant end-users (clinical pathologists). This test has an advantage compared to existing state-of-the-art staging methods in that it provides prognostic value beyond the purely anatomical TNM staging method. It is also cheaper and simpler to perform than alternative as yet clinically unvalidated biomarker test based on gene expression panels.
Validation of the biomarker in an independent set of colon cancer patients is ongoing.
Development status
Patent information
Priority patent application US. The patent application claims diagnostic, prognostic and predictive uses of the technology.
Type of business relationship sought
Inven2 AS seeks a licensee of the technology.
Related reports
Licensing contact
Company details
Inven2 AS identifies, protects and commercialises inventions and discoveries of the University of Oslo, Oslo University Hospital and other health enterprises in the south-east of Norway.
View profileRelated technologies
- Small Molecule Inhibitors of c-Met
- Doxycycline-Inducible B16 Melanoma Cell Lines Expressing CXCR4 or CCR10
- Conjugates of Ligand, Linker, and Cytotoxic Agent and Related Compositions and Methods of Use
- Human soluble FcRn and Beta2-microglobulin expressing vector
- Novel RNA biomarker, VNN1 αβ, for colorectal cancer
Related categories
- Industry sector
- Diagnostic / Biomarker-based diagnostics
- Therapeutic target
- Oncology / Colorectal cancer
- Oncology
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us